Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Viatris (VTRS)

Nasdaq Health Care Pharmaceuticals S&P 500
$19.91
+0.94 (+4.96%)
Close of Nov 06, 2026 · end-of-day data
Source: Viatris's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 06, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$11.27B$11.37B$11.82B$17.81B$16.22B$15.39B$14.69B$14.25B
Cost of revenue$7.43B$7.60B$8.15B$12.31B$9.77B$8.99B$9.12B$9.29B
Gross profit$4.00B$3.90B$3.80B$5.58B$6.50B$6.44B$5.62B$5.01B
Research & development$704.50M$639.90M$555.10M$751.10M$662.20M$805.20M$808.70M$965.90M
Selling, general & admin$2.44B$2.56B$3.34B$4.53B$4.18B$4.07B$4.10B$3.79B
Operating income$905.60M$715.50M-$210.80M-$34.00M$1.61B$766.20M$10.10M-$2.66B
Interest expense$542.30M$517.30M$497.80M$636.20M$592.40M$573.10M$550.00M$471.30M
Pre-tax income$298.40M$154.40M-$721.20M-$664.40M$2.81B$202.90M-$623.20M-$3.67B
Income tax-$54.10M$137.60M-$51.30M$604.70M$734.60M$148.20M$11.00M-$150.10M
Net income$352.50M$16.80M-$669.90M-$1.27B$2.08B$54.70M-$634.20M-$3.51B
EBITDA$3.02B$2.73B$2.01B$4.47B$4.64B$3.51B$2.90B$135.20M
EPS (basic)$0.69$0.03$-1.11$-1.05$1.71$0.05$-0.53$-3.00
EPS (diluted)$0.68$0.03$-1.11$-1.05$1.71$0.05$-0.53$-3.00
Diluted shares516.50M516.50M601.20M1.21B1.22B1.21B——
Gross margin35.5%34.3%32.1%31.3%40.1%41.8%38.3%35.2%
Operating margin8.0%6.3%-1.8%-0.2%10.0%5.0%0.1%-18.7%
Net margin3.1%0.1%-5.7%-7.1%12.8%0.4%-4.3%-24.7%

Balance sheet

fiscal years · USD
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$388.10M$475.60M$844.40M$701.20M$1.26B$991.90M$734.80M$1.32B
Short-term investments——$39.10M$38.20M$35.30M$37.00M$38.00M$40.70M
Receivables—$3.06B$4.84B$4.27B$3.81B$3.70B$3.22B$3.03B
Inventory—$2.67B$5.47B$3.98B$3.52B$3.47B$3.85B$4.00B
Total current assets—$6.76B$12.87B$10.90B$10.64B$12.98B$9.52B$9.79B
Goodwill$9.75B$9.59B$12.35B$12.11B$10.43B$9.87B$9.13B$6.75B
Total assets—$31.26B$61.55B$54.84B$50.02B$47.69B$41.50B$37.19B
Total current liabilities—$5.57B$10.56B$9.88B$6.75B$7.78B$5.78B$7.09B
Short-term debt—$1.46B$2.26B$1.86B$1.25B$1.93B$600.00K$1.93B
Long-term debt—$11.21B$22.43B$19.72B$18.02B$16.19B$14.04B$12.48B
Total debt—$12.67B$24.69B$21.58B$19.27B$18.12B$14.04B$14.41B
Total liabilities—$19.37B$38.60B$34.35B$28.95B$27.22B$22.87B$22.48B
Shareholders' equity$12.17B$0$22.95B$20.49B$21.07B$20.47B$18.64B$14.71B

Cash flow

fiscal years · USD
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$2.34B$1.80B$1.23B$3.02B$3.00B$2.90B$2.30B$2.32B
Capital expenditures$252.10M$213.20M$243.00M$457.20M$406.00M$377.00M$326.00M$378.80M
Free cash flow$2.09B$1.59B$988.80M$2.56B$2.59B$2.52B$1.98B$1.94B
Investing cash flow-$1.21B-$525.40M-$301.10M-$117.80M$1.47B-$864.50M$1.80B-$427.70M
Financing cash flow-$1.09B-$1.17B-$605.70M-$3.01B-$3.88B-$2.30B-$4.33B-$1.29B
Share buybacks$432.00M$0$0$0$0$250.00M$250.00M$500.50M
Stock-based compensation-$3.30M$56.80M$79.20M$111.20M$116.40M$180.70M$146.10M$177.70M
Depreciation & amortization$2.11B$2.02B$2.22B$4.51B$3.03B$2.74B$2.89B$2.80B

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.